Specialty pharmaceutical company focused on developing and commercializing treatments for pain and other central nervous system disorders.
Assertio Holdings, Inc., a distinguished specialty pharmaceutical firm, focuses on delivering therapeutic solutions across neurology, hospital, and pain and inflammation domains. The company's extensive portfolio includes a range of pharmaceutical products tailored to address critical medical needs. Notable offerings encompass INDOCIN, available in oral solution and suppository forms, designed for treating conditions like rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, and gouty arthritis.
Among Assertio's innovative treatments is CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) specifically formulated to alleviate migraine symptoms such as nausea, photophobia, and phonophobia. Zipsor, another NSAID, provides relief for mild to moderate acute pain, while SPRIX offers effective pain management comparable to opioid-level analgesia for short-term needs.
Assertio Holdings, Inc. also advances Otrexup, a single-dose auto-injector containing methotrexate, prescribed for adults with severe, active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis. Formerly known as Assertio Therapeutics, Inc., the company rebranded to Assertio Holdings, Inc. in May 2020, reflecting its evolution and expanded focus within the pharmaceutical landscape.
Founded in 1995 and headquartered in Lake Forest, Illinois, Assertio Holdings continues to innovate and address unmet medical needs through its specialized portfolio and strategic initiatives in pharmaceutical development and commercialization.